DaVita Inc. 2nd Quarter 2026 Results

DaVita posts strong Q2 results but omits trend data and full financial context.

Risk flags

• ●The lack of prior period financials and trend data prevents investors from assessing whether performance is improving, stable, or deteriorating. This matters because without context, single-quarter results can be misleading and may mask underlying operational or financial issues.
• ●International operations are mentioned but not broken out by revenue, profitability, or growth, leaving a gap in understanding the contribution and risk profile of non-U.S. centers. This omission is material given 595 centers are outside the United States.
• ●The company incurred a $500 million incremental term loan, increasing leverage without disclosing updated debt ratios or interest coverage. Higher debt loads can pressure future cash flow and limit strategic flexibility, especially if operating performance falters.
• ●Forward-looking guidance is provided only on a non-GAAP basis, with no reconciliation to GAAP metrics. This limits comparability and may obscure the impact of adjustments or one-time items on reported profitability.

Bottom line

DaVita's Q2 2026 announcement delivers strong headline numbers for revenue, profit, and cash flow, but omits trend data and balance sheet context necessary for a full investment assessment. The operational scale is clear, but underlying growth is modest at 0.3% year-over-year for core treatments. All major financial claims are supported, but the absence of prior period comparables and international segment detail limits the ability to judge performance momentum or risk. The $500 million new term loan increases leverage without transparency on debt metrics. Guidance for the rest of 2026 is provided, but only on an adjusted, non-GAAP basis. Investors should treat the results as a solid snapshot, not a trend, and require more disclosure on historical performance, segment profitability, and leverage to make a fully informed decision. The key takeaway: strong quarterly execution, but incomplete context for long-term conviction.

Announcement summary

(NYSE: DVA) DaVita Inc. announced financial and operating results for the quarter ended June 30, 2026, reporting consolidated revenues of $3.554 billion. Operating income for the quarter was $579 million, with a margin of 16.3%, and diluted earnings per share were $4.02. The company generated operating cash flow of $490 million and free cash flow of $256 million for the quarter. DaVita incurred an incremental Term Loan B-2 tranche in the aggregate principal amount of $500 million and repurchased 2.2 million shares of its common stock at an average price of $154.95 per share for $348 million. Total U.S. dialysis treatments for the second quarter of 2026 were 7,226,600, or an average of 92,649 treatments per day, representing a per day increase of 1.09% compared to the first quarter of 2026. The company projects adjusted operating income for 2026 between $2,150 million and $2,250 million, adjusted diluted net income per share between $14.10 and $15.20, and free cash flow between $1,000 million and $1,250 million.

Disagree with this article?